このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Biosynex マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Larry Abensur

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	9.3yrs
CEOの所有権	6.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	9.3yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Larry Abensur

9.3yrs

在職期間

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

取締役

名称	ポジション	在職期間	報酬	所有権
Larry Abensur	Chairman & CEO	9.3yrs	データなし	6.2% € 2.8m
Thierry Paper	Deputy CEO & Director	9.3yrs	€96.00k	0.99% € 444.7k
Thomas Lamy	Deputy CEO & Director	9.3yrs	データなし	1.56% € 698.8k
Felix Agbalika	Member of Scientific Advisory Board	no data	データなし	データなし
Emmanuel Drouet	Member of Scientific Advisory Board	no data	データなし	データなし
Denis Gallot	Member of Scientific Advisory Board	no data	データなし	データなし
Vincent Sapin	Member of Scientific Advisory Board	no data	データなし	データなし
Marc Noizet	Member of Scientific Advisory Board	no data	データなし	データなし
Elie Fraenckel	Director	no data	データなし	データなし

9.3yrs

平均在職期間

経験豊富なボード: 0DLの取締役会は経験豊富であると考えられます ( 9年の平均在任期間)。

Biosynex マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Biosynex SA, Annual General Meeting, Jun 07, 2024

No independent directors

No independent directors

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

CEO（最高経営責任者

在職期間

取締役

平均在職期間

マネジメント基準チェック /14